Jul 03, 2019 7:00am EDT Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone
Apr 04, 2019 7:00am EDT Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
Apr 01, 2019 7:00am EDT Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study
Mar 21, 2019 7:00am EDT Algernon Pharmaceuticals Appoints Leading Liver Disease Expert Dr. Arun Sanyal to Its Medical and Scientific Advisory Board
Feb 25, 2019 7:00am EST Algernon Pharmaceuticals Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis
